PART I . Overview We are a clinical-stage specialty immunotherapy company harnessing one of natures most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability and commercial success in the forthcoming era of medicine will rely on ensuring patie...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014326 | EDGAR | 89K words |
| 2025-04-02 | 2024-12-31 | 0001641172-25-002426 | EDGAR | — |
| 2024-04-29 | 2023-12-31 | 0001493152-24-016796 | EDGAR | — |
| 2023-04-17 | 2022-12-31 | 0001410578-23-000698 | EDGAR | — |
| 2022-04-01 | 2021-12-31 | 0001410578-22-000810 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001493152-26-038509 | EDGAR | — |
| 2025-11-14 | 2025-09-30 | 0001493152-25-022641 | EDGAR | 28K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024101 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001641172-25-010395 | EDGAR | — |
| 2024-11-19 | 2024-09-30 | 0001493152-24-046839 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032294 | EDGAR | — |
| 2024-05-28 | 2024-03-31 | 0001493152-24-021650 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040622 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001493152-23-029606 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001410578-23-001349 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001410578-22-003394 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001410578-22-002585 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-30 | 0001493152-26-035334 | EDGAR | — |
| 2026-03-25 | 0001493152-26-012701 | EDGAR | 1K words |
| 2026-03-04 | 0001493152-26-008786 | EDGAR | — |
| 2026-02-25 | 0001493152-26-008065 | EDGAR | — |
| 2026-01-30 | 0001493152-26-004461 | EDGAR | — |
| 2025-09-26 | 0001493152-25-015784 | EDGAR | — |
| 2025-07-10 | 0001641172-25-018533 | EDGAR | — |
| 2025-07-03 | 0001641172-25-017873 | EDGAR | — |
| 2025-06-30 | 0001641172-25-017198 | EDGAR | — |
| 2025-06-23 | 0001641172-25-016126 | EDGAR | — |
83 total filings indexed. 56 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001860871 |
| Ticker | TVGN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.tevogen.com |
| Listed | 2024-02-15 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TVGN (~200 tokens, structured JSON with cryptographic provenance)